The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial

  • The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial:
    • Was the first study to compare:
      • A 3rd-generation aromatase inhibitor (AI), anastrozole, with tamoxifen for the adjuvant treatment of early breast cancer
  • The ATAC trial:
    • As designed to compare the efficacy and safety of:
      • Anastrozole (1 mg) with tamoxifen (20 mg) as adjuvant treatment for postmenopausal women with early-stage breast cancer
    • Patients were treated every day for 5 years
    • The study was a double-blind, prospective, randomized trial:
      • With 9,366 postmenopausal women
    • A proportional hazards model was used to assess:
      • The primary endpoints of:
        • DFS
      • Secondary endpoints of:
        • Time to recurrence
        • Time to distant recurrence
        • Overall survival
        • Death with or without recurrence
    • The combination arm of anastrozole and tamoxifen:
      • Was discontinued after the initial analysis:
        • As it was found to have no efficacy or tolerability benefits over tamoxifen alone.
    • Long-term follow-up of 120 months showed:
      • Significant improvements in the anastrozole group versus the tamoxifen group for:
        • DFS, time to recurrence, and time to distant recurrence
      • In hormone receptor-positive patients:
        • These benefits were seen to increase over time
      • Recurrence rates were found to:
        • Remain lower on anastrozole after treatment was completed
      • There was little difference in overall survival:
        • Between anastrazole and tamoxifen (hazard ratio, 0.95; 95% confidence interval, 0.84–1.06; P=0.4)
      • Fractures were more frequent during the active treatment in patients receiving anastrozole:
        • But were similar between the two groups in post-treatment follow-up
      • Treatment-related serious adverse events:
        • Were less common in the anastrozole group:
          • But were also found to be similar between the two groups after treatment completion
        • Anastrozole showed a non-significant increased incidence of colorectal cancer and lung cancers, and a decreased incidence of endometrial, melanoma, and ovarian cancers:
          • However, only the decrease in endometrial cancers remained statistically significant after Bonferroni correction (P<0.001)
      • Overall, anastrozole was found to have:
        • Superior long-term efficacy and safety than tamoxifen as initial adjuvant therapy for postmenopausal women with hormone-sensitive early-stage breast cancer
        • Outcomes from the ATAC trial made anastrozole the preferred treatment for postmenopausal women with localized hormone receptor-positive breast cancer
  • References
    • Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
    • Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al; ATAC/LATTE Investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-1141.

#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncologist #ATAC #EndocrineTherapy #Mexico #Miami #Teacher #Surgeon

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s